FDA Clears C2N Diagnostics’ PrecivityAD2® — First Alzheimer’s Blood Test for Adults with Cognitive Symptoms as Young as 40

FDA Clears C2N Diagnostics’ PrecivityAD2® — First Alzheimer’s Blood Test for Adults with Cognitive Symptoms as Young as 40

FDA Clearance Builds on C2N’s Legacy of Delivering Transformative Solutions to Address Alzheimer’s Disease Crisis

PrecivityAD2® Becomes the First FDA-Cleared Test Powered by High Resolution Mass Spectrometry and Multiple Analyte Algorithm Score for Aiding in Diagnosis

Single Blood Test Delivers High Diagnostic Performance to Aid Health Care Professionals in Ruling-In and Ruling-Out Clinical Alzheimer’s Disease at its Earliest Stages

The U.S. Food & Drug Administration (FDA) has cleared C2N Diagnostics’ PrecivityAD2® test, providing patients and health care professionals with an accurate, accessible, and scalable blood test to help diagnose Alzheimer’s disease in conjunction with standard clinical workup. An estimated 19-20 million U.S. adults aged 65 and older, and hundreds of thousands more between ages 45 and 65 are living with cognitive impairment and may benefit from an early diagnosis1.